Navigation Links
Stem Cell Licensing Deal Positions Toronto as World Leader in Technology

A $20-million deal announced today to license Canadian stem cell technology in the U.S. underscores the Toronto areas global leadership in stem cell research .

Under the agreement, Tissue Regeneration Therapeutics Inc. (TRT), an emerging Canadian life sciences company, will exclusively license its human umbilical cord perivascular cell (HUCPVC) technology to Stem Cell Authority Ltd. for family stem cell banking in the U.S. The licensing fees and annual minimum royalties will exceed $20-million (Cdn) over the next four years. The technology originated at the University of Toronto and has been offered to the public in Canada since March 2007 through a licensing agreement between TRT and Toronto-based CReAte Cord Blood Bank (CCBB).

Toronto is the first place in the world to bank perivascular mesenchymal stem cells from the human umbilical cord and we are extremely pleased to now be able to provide this opportunity to parents across the U.S., says Professor John E. Davies at U of Ts Institute of Biomaterials and Biomedical Engineering, senior inventor of the technology. This is a great example of how a university can facilitate the translation of professorial research from the university laboratory to commercial reality for the benefit of the public.

Currently, TRT technology is available to the Canadian public through CCBB, which markets HUCPVCs as Peristem. Once the baby is born, a health professional simply collects the cord tissue and places it in a bio-container supplied with a nutrient solution and then ships it to the CReATe laboratories for processing and storage. A technician at the laboratory uses a proprietary process to remove the cells from the cord tissue and stores them for future use. Unlike cord blood stem cells, which can also be harvested, mesenchymal cells are the building blocks for the muscle, bone and connective tissues of the body. HUCPVCs also serve as regulators of the immune system. Published uses of mesenchymal cells in cell therapy include combating auto-immune and inflammatory diseases (Crohns, juvenile diabetes and rheumatoid arthritis), cancer, heart disease and tissue engineering.

While the HUCPVC technology is still in the pre-clinical stage, TRT CEO Dr. Jeffrey Turner says that its development program designed to treat auto-immune and inflammatory diseases offers parents a type of biological life insurance that could one day treat all the diseases mentioned above and more. What excites me is that our growing stem cell company in Canada is now offering its services to the U.S., which is essentially half the world market, Turner says. We are now currently looking to expand into the Middle Eastern and Australian markets.

The HUCPVC breakthrough was announced in 2005 when the Davies research group at the University of Toronto discovered these stem cells in an uncharted part of the umbilical cord the connective tissue immediately surrounding the blood vessels in the cord. The great advantages of this source of mesenchymal stem cells, compared with current techniques using surgically extracted cells from bone marrow, lie in sourcing them from tissue that would otherwise be thrown away at birth, their very rapid proliferation and the huge numbers of harvested stem cells.


'"/>




Related medicine news :

1. Ranbaxy Signs Licensing, Supply Agreement for Canadian Market
2. Merck Announces Plans for Licensing Atripla Widely in Developing World
3. PSivida, Pfizer Ink $165 Million Licensing Pact
4. Abbott Offers Aluvia to Thailand in Return for Compulsory Licensing Halt
5. Two New Anesthesia Positions Promise to Ease Surgery Queue
6. Avoid travel to Toronto - WHO
7. WHO Says Toronto Going Back on SARS-Affected List
8. Mysterious viral outbreak in Toronto, influenza ruled out
9. Satellite Clinic To Be Set Up in Toronto By Ohio-Based Cleveland Clinic
10. IOF World Congress On Osteoporosis To Be Held In Toronto
11. Hepatitis Scare in Toronto
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/20/2017)... ... July 20, 2017 , ... There’s a lot of confusing lingo out there ... the same thing. But it’s crucial to understand both the differences and similarities between ... Kaixuan Liu, MD, PhD, founder and president of Atlantic Spine Center . ...
(Date:7/20/2017)... ... , ... LINET, an international leader in healthcare technology and a global supplier ... birthing bed. , Perfectly suitable for labor, delivery, recovery and postpartum; the revolutionary design ... every phase of childbirth. The AVE 2 has many features that help make the ...
(Date:7/20/2017)... ... July 19, 2017 , ... Med Tech Solutions (MTS), a leading health ... business unit of Constellation Inc., a move that will help the company better serve ... St. Louis, the acquisition is expected to help MTS expand its presence ...
(Date:7/20/2017)... ... 2017 , ... A July 7th article on ... veins in some patients, according to medical experts. Washington State medical clinic Northwest ... sitting or standing, or regularly nicking yourself while shaving your legs, and taking ...
(Date:7/18/2017)... (PRWEB) , ... July 18, 2017 , ... ... device compliance and commercialization, has just announced two more sessions of its “From ... engineering into risk management activities. Led by David Cronin, Cognition’s CEO, the half-hour ...
Breaking Medicine News(10 mins):
(Date:7/15/2017)... 15, 2017 Enterin Inc., a Philadelphia ... disease (PD), today announced the completion of a $12.7 million ... Ventures III, as well as the participation of existing investors. ... to have the support of New Ventures III and our ... validation of the potential of our platform technology to transform ...
(Date:7/13/2017)... WILLIAMSTON, Mich. , July 13, 2017  Centurion Medical Products, ... offers its DisImpactor ® fecal impaction removal device for hospice ... ... Patient pain management ... DisImpactor for Hospice can help alleviate patient pain while preventing unneeded ...
(Date:7/12/2017)... is a revolutionary new product that relieves painful carpal tunnel syndrome ... affects more than 8 million people a year. Women suffer from ... methods of treating CTS are painful surgery, the use of NSAIDs ... ... a clear patch worn on the palm of the hand. It ...
Breaking Medicine Technology: